REPL240517C25000
- 0.10
- 0.000.00%
Replimune Newsroom
Buy Rating Affirmed: Replimune's Financial Stability and RP1's Promising Future
Analyst Jonathan Chang of Leerink Partners reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price target of $10.00.
Barclays Remains a Buy on Replimune Group (REPL)
In a report released today, Peter Lawson from Barclays maintained a Buy rating on Replimune Group (REPL), with a price target of $13.00.
Buy Recommendation for Replimune Group Based on Promising RP1 Clinical Developments and Robust Financial Outlook
J.P. Morgan analyst Anupam Rama has maintained their bullish stance on REPL stock, giving a Buy rating today.
Buy Rating Affirmed for Replimune Group Amid Positive Clinical and Regulatory Developments
Kaveri Pohlman, an analyst from BTIG, maintained the Buy rating on Replimune Group (REPL).
Replimune | 10-K: Annual report
Replimune Group Inc. Expects Enrollment Of First Patients In Phase 3 Confirmatory Trial Of RP1 In Advanced Melanoma In 2H 2024
Replimune Group Inc. Expects Enrollment Of First Patients In Phase 3 Confirmatory Trial Of RP1 In Advanced Melanoma In 2H 2024
Replimune Group FY24 Loss/Shr $3.24 >REPL
Replimune Group FY24 Loss/Shr $3.24 >REPL
Replimune Group 4Q Loss $55.1M >REPL
Replimune Group 4Q Loss $55.1M >REPL
Replimune Group: Cash Runway to Fund Ops Into 2H 2026 >REPL
Replimune Group: Cash Runway to Fund Ops Into 2H 2026 >REPL
Press Release: Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update -- Twelve-month primary analysis results by independent central review from the IG
Selling Replimune Group Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Despite the fact that Replimune Group, Inc.'s (NASDAQ:REPL) value has dropped 12% in the last week insiders who sold US$1.6m worth of stock in the past 12 months have had less success. Insiders might
Replimune Group Provides Interim Results for Skin Cancer Therapy
Replimune Group (REPL) said Sunday that a phase 1/2 clinical trial of its RP1 monotherapy for skin cancer has initially showed an overall response rate of 34.8%. The interim overall response rate come
Replimune Group Presented The Interim Results From The ARTACUS Clinical Trial Of RP1 Monotherapy In Solid Organ And Hematopoietic Cell Transplant Recipients With Skin Cancers At AACR 2024
In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partia
Interim Results From the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients With Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants, by Michael R. Midgen, M.D., of the University of Texas MD Anderson Cancer Center during an oral session at the AACR 2024 Annual Meeting in San Diego.
Analysts Are Bullish on Top Healthcare Stocks: Replimune Group (REPL), Merck & Company (MRK)
Replimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEO
Replimune Names Sushil Patel as CEO in Broader Shakeup
By Will Feuer Replimune Group, a clinical-stage biotechnology company, named Sushil Patel as its next chief executive officer, succeeding Philip Astley-Sparke, who will become executive chairman. Th
Replimune Group Announces CEO Transition
Replimune Appoints Sushil Patel To CEO Succeeding Philip Astley-sparke Effective April 1, 2024. Mr. Astley-sparke Will Transition From His Current Role As CEO To Executive Chairman Of The Board Of Director
Replimune Appoints Sushil Patel To CEO Succeeding Philip Astley-sparke Effective April 1, 2024. Mr. Astley-sparke Will Transition From His Current Role As CEO To Executive Chairman Of The Board Of Dir
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
WOBURN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced